218 related articles for article (PubMed ID: 22108637)
1. Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay.
Liang Z; Ding X; Ai J; Kong X; Chen L; Chen L; Luo C; Geng M; Liu H; Chen K; Jiang H
Org Biomol Chem; 2012 Jan; 10(2):421-30. PubMed ID: 22108637
[TBL] [Abstract][Full Text] [Related]
2. Identification and synthesis of N'-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-Met kinase.
Liang Z; Zhang D; Ai J; Chen L; Wang H; Kong X; Zheng M; Liu H; Luo C; Geng M; Jiang H; Chen K
Bioorg Med Chem Lett; 2011 Jun; 21(12):3749-54. PubMed ID: 21561768
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and molecular docking studies of some novel spiro[indoline-3, 4'-piperidine]-2-ones as potential c-Met inhibitors.
Ye L; Tian Y; Li Z; Jin H; Zhu Z; Wan S; Zhang J; Yu P; Zhang J; Wu S
Eur J Med Chem; 2012 Apr; 50():370-5. PubMed ID: 22381355
[TBL] [Abstract][Full Text] [Related]
4. The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach.
Allen JV; Bardelle C; Blades K; Buttar D; Chapman L; Colclough N; Dossetter AG; Garner AP; Girdwood A; Lambert C; Leach AG; Law B; Major J; Plant H; Slater AM
Bioorg Med Chem Lett; 2011 Sep; 21(18):5224-9. PubMed ID: 21835616
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of potent c-Met inhibitors.
D'Angelo ND; Bellon SF; Booker SK; Cheng Y; Coxon A; Dominguez C; Fellows I; Hoffman D; Hungate R; Kaplan-Lefko P; Lee MR; Li C; Liu L; Rainbeau E; Reider PJ; Rex K; Siegmund A; Sun Y; Tasker AS; Xi N; Xu S; Yang Y; Zhang Y; Burgess TL; Dussault I; Kim TS
J Med Chem; 2008 Sep; 51(18):5766-79. PubMed ID: 18763753
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
[TBL] [Abstract][Full Text] [Related]
7. Indazoles as potential c-Met inhibitors: design, synthesis and molecular docking studies.
Ye L; Ou X; Tian Y; Yu B; Luo Y; Feng B; Lin H; Zhang J; Wu S
Eur J Med Chem; 2013 Jul; 65():112-8. PubMed ID: 23702473
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase.
Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H
Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525
[TBL] [Abstract][Full Text] [Related]
9. O-linked triazolotriazines: potent and selective c-Met inhibitors.
Chen F; Wang Y; Ai J; Zhan Z; Lv Y; Liang Z; Luo C; Mei D; Geng M; Duan W
ChemMedChem; 2012 Jul; 7(7):1276-85. PubMed ID: 22539497
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-azaindoles as novel inhibitors of c-Met kinase.
Porter J; Lumb S; Franklin RJ; Gascon-Simorte JM; Calmiano M; Riche KL; Lallemand B; Keyaerts J; Edwards H; Maloney A; Delgado J; King L; Foley A; Lecomte F; Reuberson J; Meier C; Batchelor M
Bioorg Med Chem Lett; 2009 May; 19(10):2780-4. PubMed ID: 19369077
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
[TBL] [Abstract][Full Text] [Related]
12. Strategy for discovering chemical inhibitors of human cyclophilin a: focused library design, virtual screening, chemical synthesis and bioassay.
Li J; Zhang J; Chen J; Luo X; Zhu W; Shen J; Liu H; Shen X; Jiang H
J Comb Chem; 2006; 8(3):326-37. PubMed ID: 16677001
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
[TBL] [Abstract][Full Text] [Related]
14. Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.
Bode CM; Boezio AA; Albrecht BK; Bellon SF; Berry L; Broome MA; Choquette D; Dussault I; Lewis RT; Lin MH; Rex K; Whittington DA; Yang Y; Harmange JC
Bioorg Med Chem Lett; 2012 Jun; 22(12):4089-93. PubMed ID: 22595176
[TBL] [Abstract][Full Text] [Related]
15. Discovering potent inhibitors against the beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ) of Helicobacter pylori: structure-based design, synthesis, bioassay, and crystal structure determination.
He L; Zhang L; Liu X; Li X; Zheng M; Li H; Yu K; Chen K; Shen X; Jiang H; Liu H
J Med Chem; 2009 Apr; 52(8):2465-81. PubMed ID: 19309082
[TBL] [Abstract][Full Text] [Related]
16. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and evaluation of highly selective pyridone-based class II MET inhibitors.
She N; Zhuo L; Jiang W; Zhu X; Wang J; Ming Z; Zhao X; Cong X; Huang W
Bioorg Med Chem Lett; 2014 Aug; 24(15):3351-5. PubMed ID: 24951334
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazone scaffolds as selective c-Met inhibitors.
Qi B; Tao H; Wu D; Bai J; Shi Y; Gong P
Arch Pharm (Weinheim); 2013 Aug; 346(8):596-609. PubMed ID: 23843304
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors.
Ryu JW; Han SY; Yun JI; Choi SU; Jung H; Ha JD; Cho SY; Lee CO; Kang NS; Koh JS; Kim HR; Lee J
Bioorg Med Chem Lett; 2011 Dec; 21(23):7185-8. PubMed ID: 22001029
[TBL] [Abstract][Full Text] [Related]
20. Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors.
Wang Y; Xu ZL; Ai J; Peng X; Lin JP; Ji YC; Geng MY; Long YQ
Org Biomol Chem; 2013 Mar; 11(9):1545-62. PubMed ID: 23188156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
